Particularidades clave sobre bonuskong para una estrategia de inversión inteligente

En el dinámico mundo de las inversiones, la búsqueda de plataformas que ofrezcan oportunidades atractivas es constante. En este contexto, bonuskong se presenta como una opción que ha captado la atención de muchos inversores, prometiendo beneficios y un enfoque innovador. Comprender a fondo sus particularidades es crucial para evaluar si se ajusta a tus objetivos financieros y tolerancia al riesgo. El panorama de las inversiones online está en constante evolución, y es vital mantenerse informado para tomar decisiones inteligentes y rentables.

Esta guía tiene como objetivo brindar una visión completa de bonuskong, analizando sus características, ventajas, desventajas y los aspectos clave que debes considerar antes de invertir. Exploraremos cómo funciona la plataforma, los tipos de inversiones disponibles, las comisiones aplicables y las medidas de seguridad implementadas. Nuestro propósito es proporcionarte la información necesaria para que puedas realizar una evaluación objetiva y determinar si bonuskong es la opción adecuada para ti, considerando tus necesidades y expectativas como inversor.

La Plataforma BonusKong: Un Análisis Detallado

Bonuskong se posiciona en el mercado como una plataforma de inversión digital que busca conectar a inversores con una variedad de oportunidades, enfocándose en la accesibilidad y la simplicidad. Su interfaz intuitiva y sus herramientas de gestión de inversiones la hacen atractiva para principiantes, pero también ofrece opciones para inversores más experimentados que buscan diversificar su portafolio. La plataforma se distingue por su enfoque en la transparencia y la seguridad, implementando medidas para proteger los fondos de los inversores y garantizar la integridad de las transacciones.

Una de las principales ventajas de bonuskong es su capacidad para ofrecer acceso a mercados que tradicionalmente eran exclusivos para inversores institucionales o con grandes capitales. Esto democratiza la inversión, permitiendo que personas con recursos limitados puedan participar en oportunidades rentables. Sin embargo, es importante tener en cuenta que las inversiones siempre conllevan riesgos, y es fundamental comprenderlos antes de tomar cualquier decisión. La plataforma ofrece recursos educativos y herramientas de análisis para ayudar a los inversores a tomar decisiones informadas.

Rendimiento y Opciones de Inversión

El rendimiento que se puede obtener a través de bonuskong varía dependiendo del tipo de inversión elegida y las condiciones del mercado. La plataforma ofrece una gama de opciones que incluyen acciones, bonos, criptomonedas y fondos de inversión. Cada una de estas opciones tiene su propio perfil de riesgo y potencial de rentabilidad, por lo que es importante investigar y comprender las características de cada una antes de invertir. Las condiciones económicas globales, así como la situación política y social, pueden influir significativamente en los rendimientos de las inversiones en la plataforma.

Bonuskong facilita la diversificación del portafolio, permitiendo a los inversores distribuir sus fondos en diferentes activos para reducir el riesgo. La diversificación es una estrategia clave para protegerse contra las fluctuaciones del mercado y aumentar las posibilidades de obtener rendimientos consistentes a largo plazo. Es importante recordar que la diversificación no garantiza ganancias, pero puede ayudar a mitigar las pérdidas en caso de que una inversión no funcione como se esperaba.

Tipo de Inversión	Riesgo	Rentabilidad Potencial
Acciones	Alto	Alto
Bonos	Moderado	Moderado
Criptomonedas	Muy Alto	Muy Alto
Fondos de Inversión	Variable	Variable

Como se puede observar en la tabla, la relación entre riesgo y rentabilidad potencial es directa; a mayor riesgo, mayor potencial de rentabilidad, y viceversa. La elección del tipo de inversión adecuado dependerá de tus objetivos financieros, tu tolerancia al riesgo y tu horizonte de inversión.

Comisiones y Tarifas en BonusKong

Uno de los aspectos cruciales a considerar al elegir una plataforma de inversión son las comisiones y tarifas que se aplican. Bonuskong cobra comisiones por transacción, gestión de cuentas y, en algunos casos, por retiros de fondos. Es importante comprender la estructura de comisiones antes de comenzar a invertir, ya que pueden afectar significativamente tus rendimientos netos. La transparencia en las comisiones es un indicador de la confiabilidad de la plataforma.

Las comisiones de bonuskong se encuentran dentro del rango estándar del mercado, pero es importante compararlas con las de otras plataformas para asegurarse de obtener el mejor valor. Algunas plataformas ofrecen comisiones más bajas, pero pueden tener otras tarifas ocultas o limitaciones en cuanto a las opciones de inversión disponibles. Es fundamental leer detenidamente los términos y condiciones de la plataforma antes de abrir una cuenta.

Impacto de las Comisiones en la Rentabilidad

Las comisiones pueden tener un impacto significativo en la rentabilidad a largo plazo de tus inversiones. Incluso pequeñas comisiones pueden acumularse con el tiempo y erosionar tus ganancias. Por lo tanto, es importante tener en cuenta las comisiones al evaluar diferentes opciones de inversión. Una estrategia para minimizar el impacto de las comisiones es invertir a largo plazo, ya que el tiempo permite que las ganancias superen las costos asociados.

Asegúrate de entender cómo se calculan las comisiones y cuándo se aplican. Algunas plataformas cobran comisiones fijas por transacción, mientras que otras cobran un porcentaje del monto invertido. También es importante considerar las posibles tarifas por inactividad o por mantenimiento de la cuenta.

• Comisiones por transacción: Un porcentaje del monto de cada operación.
• Comisiones de gestión: Un cargo anual o mensual por la administración de tu cuenta.
• Comisiones por retiro: Un cargo por retirar fondos de tu cuenta.
• Comisiones por inactividad: Un cargo si no realizas operaciones durante un período determinado.

La claridad y la transparencia en las comisiones son fundamentales para construir una relación de confianza con la plataforma de inversión.

Seguridad y Regulación de BonusKong

La seguridad de tus fondos es una preocupación primordial al invertir en cualquier plataforma online. Bonuskong implementa medidas de seguridad avanzadas para proteger tu información personal y financiera, incluyendo encriptación de datos, autenticación de dos factores y sistemas de detección de fraude. Sin embargo, es importante recordar que ninguna plataforma es completamente inmune a los riesgos de seguridad.

La regulación de la plataforma también es un factor importante a considerar. Bonuskong está regulada por [Insertar nombre del organismo regulador], lo que significa que está sujeta a supervisión y debe cumplir con ciertos estándares de seguridad y transparencia. La regulación proporciona un nivel adicional de protección para los inversores.

Medidas de Seguridad Adicionales

Además de las medidas de seguridad implementadas por la plataforma, existen algunas medidas que puedes tomar para proteger tus fondos. Utiliza contraseñas seguras y únicas para tu cuenta de bonuskong y para tus cuentas de correo electrónico. No compartas tu información de inicio de sesión con nadie. Mantén tu software antivirus actualizado y ten cuidado con los correos electrónicos o enlaces sospechosos.

1. Utiliza contraseñas seguras y únicas.
2. Habilita la autenticación de dos factores.
3. Mantén tu software antivirus actualizado.
4. Ten cuidado con los correos electrónicos y enlaces sospechosos.
5. Revisa regularmente tus transacciones.

La combinación de las medidas de seguridad implementadas por la plataforma y tus propias precauciones puede ayudarte a minimizar el riesgo de fraude y proteger tus inversiones.

Ventajas y Desventajas de Invertir con BonusKong

Como cualquier plataforma de inversión, bonuskong tiene sus propias ventajas y desventajas. Entre las ventajas se encuentran su facilidad de uso, su acceso a una amplia gama de opciones de inversión y su enfoque en la transparencia. Entre las desventajas se encuentran las comisiones aplicables y los riesgos asociados con la inversión online.

Es importante sopesar cuidadosamente las ventajas y desventajas antes de decidir si bonuskong es la opción adecuada para ti. Considera tus objetivos financieros, tu tolerancia al riesgo y tu nivel de experiencia en inversiones.

Consideraciones Finales sobre la Gestión de Riesgos en BonusKong

Invertir en cualquier plataforma, incluyendo bonuskong, implica inherentemente un nivel de riesgo. La volatilidad del mercado, los eventos económicos inesperados y las decisiones individuales pueden influir en el rendimiento de tus inversiones. Por ello, la gestión de riesgos se convierte en una herramienta fundamental para proteger tu capital y optimizar tus potenciales ganancias. Una estrategia efectiva implica diversificar tu portafolio, asignando tus fondos a diferentes clases de activos y sectores para mitigar el impacto de una posible pérdida en una sola inversión.

Además, es crucial establecer un horizonte de inversión claro y alinear tus inversiones con tus objetivos financieros a largo plazo, evitando decisiones impulsivas basadas en fluctuaciones del mercado a corto plazo. Realizar un seguimiento regular de tus inversiones y reajustar tu portafolio según sea necesario es también una práctica recomendable para mantener una estrategia de inversión sólida y adaptable a las condiciones cambiantes del mercado. Recuerda que la paciencia y la disciplina son cualidades esenciales para un inversor exitoso.

Why SpinBond Appeals to Quick‑Hit Players

For those who thrive on adrenaline and instant gratification, SpinBond Casino offers a streamlined experience that cuts straight to the action. The platform is built around short bursts of gameplay, where a single spin can deliver a payoff within seconds. Players accustomed to high‑energy sessions appreciate the emphasis on rapid returns and minimal downtime.

The casino’s interface is intentionally uncluttered, with a clear navigation bar that highlights the most popular slots and promotions. When you click a game title like Aztec’s Millions or Sugar Rush, the loading time is negligible, and the first round of spins begins almost immediately. This design choice keeps the momentum alive and prevents the frustration that can come with long queue times.

SpinBond’s commitment to quick outcomes is evident in its bonus structure and game selection. The welcome offer— a 200% match up to $1,000 plus free spins— is activated with a single deposit, and the wagering requirements are transparent from the outset.

Fast‑Track Bonuses for Rapid Action

The welcome package is tailored for players who want to hit the ground running. Once you deposit $20 or more, you receive double your stake up to $1,000 instantly. The bonus funds are available for immediate use on slots like Coyote Cash 2 or Hot Pots Master. The only catch is a standard 30x wagering requirement on the matched bonus and a separate 40x on free spin winnings.

Because the bonus is activated instantly, you can test your luck without waiting for manual approval. The system also displays a countdown timer that reminds you of any daily reload offers, promoting continuity without long breaks.

What makes this bonus fast‑track friendly is its simplicity—no complex steps or hidden terms that could delay gameplay. As soon as the bonus is credited, your credit line is higher by the matched amount, allowing you to place larger bets if you feel confident.

Game Picks for the Speedster: Top Slots in Minutes

If you’re looking for games that deliver quick outcomes without sacrificing excitement, SpinBond’s library offers several options that fit the bill:

• Aztec’s Millions – A classic reel‑spin with an instant scatter feature.
• Sweet 16 – A fruity theme where combinations payout on every spin.
• Fruit Bowl XXV – Clean symbols and a fast payout cycle.
• Cubee Time Travel Adventure – Short rounds with a chance for free spins.

Each of these titles has been chosen for their ability to provide an engaging experience within a single session of under ten minutes. Players can test multiple slots in rapid succession, keeping their adrenaline high while evaluating which machine offers the best return in the shortest time.

Mobile‑First Design: Spin Anywhere, Anytime

The entire SpinBond experience is optimized for mobile browsers, meaning there’s no need to download an app or install additional software. Whether you’re on an iPhone, Android phone, or tablet, the layout adapts instantly to your device’s screen size.

This mobile focus is particularly appealing to players who enjoy short sessions during commutes or lunch breaks. You can launch a game while waiting in line, spin for a few minutes, and then leave the session open for later if you wish to continue.

The responsive design ensures that buttons are large enough for touch interaction and that loading times remain minimal across all devices—critical for maintaining a high‑intensity gameplay rhythm.

Payment Flexibility: Jump‑Start Your Play

SpinBond offers a range of payment methods that cater to fast deposits:

• Credit Cards – Visa and MasterCard allow instant transfers.
• Cryptocurrency – Bitcoin deposits are processed within minutes.
• E‑Wallets – eZeeWallet and PayID provide quick options especially popular in Australia.

The instant credit feature means that after confirming your payment details, your balance is updated immediately. This eliminates any waiting period that could dampen your excitement before you start spinning.

The withdrawal process is also streamlined; most funds can be moved to your chosen method within a few hours once the transaction is approved.

Session Flow: From Bet to Cashout in Seconds

A typical short session at SpinBond might look like this:

1. Deposit: Drop $50 via PayID.
2. Select Game: Pick Coyote Cash 2.
3. Place Bet: Set a modest stake of $1 per spin.
4. Spin: Hit a jackpot within five spins.
5. Payout: Receive $500 instantly in your wallet.
6. Cash Out: Withdraw $250 via Bitcoin—completed in under an hour.

This flow demonstrates how players can achieve substantial returns without long waiting periods or repeated login attempts. The process stays tight and focused on delivering results quickly.

Risk Management on the Go

Short‑session players often adopt a cautious approach to betting while still seeking excitement. A common strategy involves setting a small bankroll—say $20—and only wagering $1 per spin. This keeps losses manageable while still allowing multiple attempts at hitting a win.

The casino’s slot selection includes features like auto‑bet timers and spin limits that help players stay within their comfort zone. If a player notices a streak of losses, they can pause or stop entirely without any penalty.

The risk–reward balance is further supported by low minimum bets across most titles, ensuring that even conservative players can participate fully without feeling excluded by high stakes.

Daily Reloads and Quick Rewards

A daily reload promotion keeps momentum high by offering an extra $100 when you deposit again each day. This reward encourages regular play without requiring large sums—perfect for short bursts of action.

• $50 Reload Offer: Code DAILYSPIN50—available every day for up to $200.
• $25 Free Chip: Code WEEKENDCHIP25—available on Saturdays and Sundays.
• Loyalty Spins: Depending on your level, receive between 20–100 free spins per session.

These incentives are announced via pop‑up messages during gameplay, allowing players to seize them instantly without interrupting their session flow.

Community Vibes: A Fast‑Paced Social Scene

The SpinBond community thrives on quick interactions. Players often share short messages about big wins or near misses in live chat windows that appear during gameplay sessions.

The social aspect is further enhanced by leaderboard displays that update after each spin. Even in a brief session, you can see if you’ve outperformed others in real time—a motivating factor for those who enjoy competitive play.

The community chat also offers quick tips on which slots are currently hot, helping players decide where to place their next bet within seconds.

Wrap‑Up: Grab Your SpinBond Bonus and Go!

If you’re ready for nonstop action and instant payouts, Spin Bond Casino’s setup is ready when you are. With instant deposits, quick bonuses, mobile optimization, and a carefully curated selection of slots designed for short bursts of excitement, this platform delivers exactly what high‑intensity players crave.

Your first step? Make a deposit of $20 or more using PayID or Bitcoin—both process instantly—and claim the welcome bonus so your bankroll jumps right into action. Once you’ve spun your favorite titles like Sweet 16 or Fruit Bowl XXV and felt that rush of quick wins, you’ll understand why SpinBond Casino is the go-to destination for players who want big thrills in short sessions.

Get Your Bonus Now!

Effective today, new Minamata Convention amendment will protect children from amalgam use

Dear Friends,

The Children’s Amendment to the amalgam reduction requirement of the Minamata Convention enters
into force today, 24 June 2022!

At the 4th Conference of the Parties in Indonesia last March, our powerhouse coalition, the World
Alliance for Mercury-Free Dentistry, succeeded in gaining protection from dental amalgam for the
most vulnerable consumers. We won the Children’s Amendment, which requires that Parties “Exclude
or not allow, by taking measures as appropriate, or recommend against the use of dental amalgam for
the dental treatment of deciduous teeth, of patients under 15 years and of pregnant and
breastfeeding women…”

Today, that amendment goes into effect. From this date forward, all of the 137 nations who are
Parties to the treaty (except a handful called “opt-in” parties) must take affirmative steps –
ranging from recommendations to complete abolition – to end amalgam use for children, pregnant
women, and breastfeeding mothers. We have succeeded in shifting the Minamata Convention’s emphasis
on phasing down amalgam use to phasing it out, starting with the populations most susceptible to
the neurotoxic effects of mercury.

Now our worldwide team is putting the heat on governments everywhere to fully

The children of the world win!
https://mail.aol.com/webm

enforce the Children’s Amendment. The U.S. Food and Drug Administration (FDA) has issued a safety
communication cautioning against amalgam use for high-risk populations, including children and most
women of childbearing age. But there’s still work to do, as this revealing recent article
explains…

“…we know that many government programs, including Medicaid and the Indian Health Service,
continue to place mercury fillings in children’s mouths—in defiance of the FDA’s warnings.”

We will not let any country – including the United States – take a pass on protecting everybody,
especially our children, from dental mercury exposure.

Charlie
24 June 2022

Charles G. Brown
National Counsel, Consumers for Dental Choice President, World Alliance for Mercury-Free Dentistry
New Address: 727 15th St. NW, Suite 701, Washington, DC 20005 USA Phone: 202-544-6333
www.ToxicTeeth.org

Opinion: The FDA is in a Hole With MOU on Compounding Medications—It Should Stop Digging

June 21, 2022Scott Brunner, CAE

Congress expected the FDA to draft a memorandum of understanding on interstate distributions of compounded medications that states would be willing to sign, but that’s not what the agency did.

When FDA lawyers conceded in Federal Court in February that the agency had not properly followed Congress’ instructions for creating a memorandum of understanding (MOU) with states regarding interstate distributions of compounded medications, they finally seemed to be heeding Will Rogers’ advice: “If you find yourself in a hole, stop digging.”

For the FDA, that hole is now 25 years deep. Its impetus was a directive from Congress in 1997—part of revisions made to the Food, Drug & Cosmetic Act—that the agency execute an MOU under which state boards of pharmacy would report to the FDA certain information about state-licensed compounding pharmacies that distributed a large percentage of their compounded preparations across state lines.

As Congress conceived it, the MOU would be voluntary, but the law would impose restrictions on pharmacies shipping compounded drugs from states that chose not to sign it. Congress intended it to be a consensus document, created via the formal rule-making process, with input and endorsement of the states. In other words, Congress expected the FDA to draft an MOU that states would be willing to sign.

But that’s not what the agency did. Instead, it started digging. After several proposed iterations spanning 24 years, the FDA in 2020 finalized an MOU that:

• Did not go through formal notice-and-comment rulemaking.

• Failed to properly assess the economic impact on pharmacies and state boards of pharmacy.

• Conflated 2 important pharmacy law definitions: “distribute” and “dispense.”

That resulted in a lawsuit against the agency by 7 compounding pharmacies, whose arguments resonated in part with a federal judge and led to the FDA conceding its failures in court last February. Granted, the agency didn’t entirely abandon its shovel in that court appearance. Instead, it laid out plans for starting work on a new hole: proposing yet another version of the MOU, this time via the prescribed rule-making process it previously failed to follow.

But abandoning that MOU is precisely what the FDA ought to seek permission to do, because the specific problem the MOU was conceived in 1997 to address no longer exists.

To understand why the MOU as envisioned by Congress is out of date, let’s first return to those definitions mentioned earlier. Across federal and state pharmacy law, the terms “distribute” and “dispense” have remarkably consistent definitions.

“Dispensing” is patient-specific; it refers to a drug prepared for an individual patient pursuant to a prescription from a physician or other prescriber. “Distributions,” on the other hand, are not patient-specific; the term applies to batches of compounded medications prepared for in-clinic or in-hospital administration by a physician to a patient, and a prescription is not required.

Back in 1997 when Congress authorized creating the MOU, it was to address compounding and distribution by traditional compounding pharmacies of non-patient-specific medications intended for in-clinic administration. It was a practice generally allowed under most states’ laws at the time but was subsequently prohibited by Congress when it passed the Drug Quality & Security Act (DQSA) in 2013.

Under the DQSA, traditional compounders were forbidden from compounding drugs for in-clinic use without a prescription. Not only that, but a new category of compounding operation, called outsourcing facilities, was created. Those facilities would be allowed to distribute compounded medications to hospitals and clinics if they adhered to current good manufacturing practices, much like the manufacturers of FDA-approved drugs do.

The DQSA eliminated the need for that 1997 MOU because traditional compounders could no longer do what the MOU was envisioned to illuminate. Still, the requirement for an MOU remained in the Food, Drug & Cosmetic Act, so the FDA decided to dig a little deeper.

The agency re-drafted an MOU that applied to both distributions and dispensing of compounded medications—even though Congress had only authorized the MOU to cover distributions, and not patient-specific dispensing, regulation of which has long been the purview of state boards of pharmacy. That overreach led to the aforementioned lawsuit against the agency by compounding pharmacies and that February court appearance where the FDA climbed out of one hole and announced it would start another.

Here’s the thing, pharmacy compounders are not opposed to some level of reporting on shipments of compounded medications across state lines—even shipping of patient-specific compounded drugs. Because it’s not unusual in compounding that the pharmacy that makes that customized drug for your partner, your child, or your Aunt Sadie is in a different state, it’s not unreasonable for state boards of pharmacy and the FDA to want to know which pharmacies are shipping majorities of their compounded preparations out of state.

So instead of digging a new hole, the FDA should join with the compounding profession to change the law. Eliminate that out-of-date MOU requirement—an MOU that several states have already said they can’t sign (because of state law) or won’t sign (because of the administrative burden).

In its place create a statutory regime for reporting shipping info to state boards of pharmacy, to be shared with FDA. Maybe also create a narrow but permanent pathway in the statute for compounding pharmacies to mitigate drug supply chain problems by preparing urgent-use drugs in small batches for hospitals and clinics when those drugs are in national or regional shortage.

Stop digging FDA, and let’s start building a new framework that provides the reporting you want and maintains patient access to safe, life-enhancing compounded medications.

About the Author

Scott Brunner, CAE, is chief executive officer of the Alliance for Pharmacy Compounding.

https://tcih.org/

This link leads to an international declaration about integrative and alternative medicine: www.tcih.org/read

At the June 14th meeting, the board voted to become a signatory to this declaration.

 

 

FDA will hold a drug compounding annual listening session, virtually, from 9-11 a.m. ET on June 17. This listening session is an opportunity for stakeholders to voice their views on compounding to the FDA. Dr. Mary Ann Block met with IMC members this week for guidance in using her 5 minute opportunity. Alan Dumoff also plans to testify.

Filed Electronically at Regulations.gov
May 24, 2022
Pharmacy Compounding Advisory Committee
Center for Drug Evaluation and Research
US Food and Drug Administration
5630 Fishers Lane
Rockville, MD 20852
Re: Comments on Docket FDA-2021-N-0357
Message to PCAC Members regarding Glutathione
Dear PCAC Committee Members:
I write on behalf of the American Association of Naturopathic Physicians (AANP), one of the
nominators of glutathione.1 While the FDA appears to have provided an in-depth analysis that supports
its rejection of this important therapy, the rubric applied is deeply faulty and sharply slanted to yield
recommendations against the inclusion of safe and effective therapies on the positive list. While many
of the details provided are subject to challenge, the less obvious but more critical point is that the
standards being applied to these reviews are contrary to statute and poor public health policy. I begin
by writing of my own experience as it perfectly encapsulates the profound flaws in the FDA’s
ingredient review process and its recommendation against the inclusion of glutathione in the positive
list.2 I highlight the salient points from my experience and then expand on each below.
1 AANP has been partnered in these efforts with the Integrative Medicine Consortium
(IMC), the American Academy of Environmental Medicine (AAEM), the American College for
Advancement in Medicine (ACAM), the International College of Integrative Medicine (ICIM) and the
Academy of Integrative Health and Medicine (AIHM). Together we filed a detailed Citizens Petition
raising this and numerous other defects in the review process which can be found
https://www.regulations.gov/document/FDA-2019-P-1351-0001,
2 I would have preferred to also present to the Committee live at the meeting, but the
federal register notice gave only 11 days to learn of it and file the request for a public speaker slot. We
and many other stakeholders have complained repeatedly about the lack of notice given at every step of
the process, which is a disservice to us and to the Committee who deserves to have the input of those
with actual clinical experience about nominated ingredients. The inadequate timing has been ongoing
and appears intentionally designed to reduce public opposition. See for e.g., my correspondence in the
June 6, 2022 Briefing Package at 105-6.
The American Association of Naturopathic Physicians
300 New Jersey Avenue, NW, Suite 900 – Washington, DC 20001
Toll Free: 202-237-8150 – Fax: 202-237-8152
www.naturopathic.orgAANP Comments on Docket FDA-2021-N-0357 Regarding Glutathione
Alan Dumoff, JD, MSW
May 24, 2022
Page 2
My Encounter with Glutathione
Due to several inhalation mishaps that damaged my lungs, I spoke with about seven of my
client functional medicine and naturopathic doctors3 who all recommended that I nebulize glutathione.
Every doctor I talked with occasionally nebulized glutathione themselves as well as recommended it
for their patients, reporting considerable success. I have been nebulizing glutathione off and for the past
several years and found it to be profoundly helpful. My experience contrasts with FDA’s requirements
in a number of critical ways:
Functional Therapies Not Allowed. Note that I am not being treated for a specific “disease,” I
am using it to heal these injuries and improve lung function. It was not suggested to me by consulting a
diagnostic decision tree with a pathway through FDA’s narrow disease lens but because of its known,
direct therapeutic effects. Glutathione has been used for decades by physicians with a functional
approach to care4 to obtain benefits as an antioxidant, anti-inflammatory and detoxification agent and
for other therapeutic functional purposes. It may not be obvious to members of the Committee that
FDA’s position is that even demonstrated therapeutic effects are insufficient to allow use, but have
imposed a disease requirement without statutory basis and which serves no public health purpose. It
does allow the Agency to require proof supporting a disease indication even where use is generally as a
functional therapy. While we believe the disease standard has been met, FDA is engaged in
misdirection by focusing on this artificially imposed threshold.
3 Naturopathic medical schools provide equivalent foundational coursework as MD and
DO schools, including pharmacology, cardiology, neurology, radiology, obstetrics, gynecology,
immunology, dermatology, and pediatrics. Degrees are awarded after extensive classroom study,
clinical training and an extensive postdoctoral exam. ND training includes the prescription of clinical
doses of vitamins and herbs and safe administration via oral, topical, IM and IV routes. Currently, 27
states and territories license NDs to practice. In 9 of those states, NDs function as primary care
physicians with prescribing rights. Naturopathic physicians have an excellent safety record with
licensing boards and a low incidence of malpractice.
4 To ensure it is clear, functional physicians are fully trained and licensed medical doctors
whose practice focus and training is in an approach that considers metabolic, immune, and other
functional vectors in an effort to seek underlying causes of disease that are often highly individualized.
Their differential decisions about use of compounded ingredients includes consideration of the
therapeutic use of nutritional ingredients for their functional effects and are well-developed. See for e.g.
Gaby A. Nutritional Medicine, Fritz Perlberg Publishing (2011) (1326 pages); Werbach M., Moss J.,
Textbook of Nutritional Medicine, Third Line (1999) (740 pages); Katz D. Nutrition in Clinical
Practice: A Comprehensive, Evidence-Based Manual for the Practitioner (2nd Ed.) LMW (2008) (592
pages); Kligler B, Lee RA, Integrative Medicine: Principles for Practice, McGraw-Hill (2004) (700
pages); Rakel, D. Integrative Medicine (4th Ed.) (2017) (1152 pages). Naturopathic medicine also has a
strong evidence base exhibited in text books for that field, including Pizzorno J. et al. The Clinician’s
Handbook of Natural Medicine, Churchill Livingstone (3rd Ed. 2015) (1008 pages).

26 May 2022   APC amicus brief addresses ambiguity in FDA insanitary conditions guidance      “Insanitary conditions” are whatever FDA says they are. This is neither legal nor fair.   That’s the gist of APC’s argument in a “friend of the court” brief filed in U.S. District Court in New Jersey on May 13.   Funded by member contributions to the APC’s Legal Action Fund, the amicus brief was authorized in response to an urgent request from Wedgewood Pharmacy that APC support its filing for a temporary restraining order against FDA.    Wedgewood filed its papers seeking a TRO on May 5, 2022, only after FDA demanded that Wedgewood immediately recall all nonsterile products within their expiry period, gave the pharmacy only 24 hours to respond, and failed to provide the pharmacy any information supporting the need for such an extraordinary, broad recall. Wedgewood told the court it suspected that, without the TRO, FDA would move quickly to publish a news release impugning Wedgewood based on FDA’s unsubstantiated findings of “insanitary conditions” at the pharmacy.     In the TRO filing, Wedgewood and its lawyers argued that FDA had inspected the pharmacy and issued eight observations in a Form 483 related to vague notions of insanitary conditions, which focused on areas well outside the pharmacy’s compounding areas. Wedgewood further stated that none of the observations listed on the Form 483 FDA violated applicable USP standards.   APC’s amicus brief, approved by the Executive Committee*, focused solely on the lack of standards in FDA’s Insanitary Conditions GFI and FDA’s failure to promulgate any enforceable rules concerning the same.   APC engaged in the matter because we were—and remain—concerned about the significant implications on other APC-member compounding pharmacies if FDA continues to impose what appears to be the vague, subjective disciplinary standard suffered by Wedgewood. In particular, FDA derives its enforcement authority from a non-binding guidance document that contains not any objective standards, but instead relies on what appears to be a bunch of examples and the nebulous statement that “other conditions not described in the guidance may also be considered unsanitary.” How is a compounder to know what is in fact violative conduct?   In that vein, we argue in the amicus that a pharmacy “would have no basis to know under the plain meaning of the term ‘insanitary conditions’ or under the explanation set forth in the Insanitary Conditions Guidance that ‘observed personnel who moved rapidly in a sterile compounding area’ or who ‘was noted to have their safety glasses down on their nose’ would meet the standard for insanitary conditions.” Both of those were among FDA’s Form 483 observations against Wedgewood.   Last week the District Court denied Wedgewood’s request for a TRO. The judge said she could not issue a restraining order on an action that had not yet occurred—in this case, FDA’s publishing of a damning press release. But during oral argument, she also made clear that she expected FDA to work with Wedgewood to settle their difference and seemed to suggest she wanted that to occur without FDA publishing a news release that could unnecessarily damage Wedgewood’s reputation based on unsubstantiated or exaggerated claims of “insanitary conditions.”   While APC strongly supports the maintenance of sanitary workspaces where compounded drugs are prepared—it’s simply essential for assuring patient safety—there must be standards for what constitute “insanitary conditions,” and those standards need to be rooted in science and the law. Our amicus brief in this matter is the clearest elucidation of the flaws in FDA’s Insanitary Condition Guidance I’ve seen. I do urge you to read it.   APC is proud of our involvement in this matter. Just another way we’re looking out for you.    Best,

 

The FDA is reconvening their Pharmacy Compounding Advisory Board Committee (PCAC).  On the agenda for this meeting is compounded glutathione.  The agenda can be seen on the hyperlink below.  Practitioners and patients can comment only until the end of May 24th.  The American Association of Naturopathic Physicians (AANP)  have created an action alert link making it easy to comment.  Practitioners and patients should share how important compounded glutathione is to their practice and to their personal health. 

Here is the AANP action alert that is out regarding compounded glutathione. The FDA/PCAC request for comment docket on compounded glutathione is open until tomorrow, May 24th, for comment.